848498-98-6

Basic information

• Product Name: 2,6-dichloro-N-methoxy-N-methylisonicotinamide
• Synonyms: 2,6-dichloro-N-methoxy-N-methylisonicotinamide
• CAS NO: 848498-98-6
• Molecular Formula: C₈H₈Cl₂N₂O₂
• Molecular Weight: 235.06732
• Mol File: 848498-98-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,6-dichloro-N-methoxy-N-methylisonicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dichloro-N-methoxy-N-methylisonicotinamide(848498-98-6)
• EPA Substance Registry System: 2,6-dichloro-N-methoxy-N-methylisonicotinamide(848498-98-6)

Safety Data

• Hazardous Substances Data: 848498-98-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-dichloro-N-methoxy-N-methylisonicotinamide is used as an intermediate in the synthesis of pharmaceuticals for its potential therapeutic applications. Its unique structure allows it to be a key component in the development of new drugs with various medicinal properties.
Used in Agrochemical Industry:
2,6-dichloro-N-methoxy-N-methylisonicotinamide is also utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used as an Anti-inflammatory and Analgesic Agent:
2,6-dichloro-N-methoxy-N-methylisonicotinamide has been studied for its potential use as an anti-inflammatory and analgesic agent, offering relief from pain and reducing inflammation in various conditions.
Used as a Precursor in Organic Synthesis:
Due to its versatile structure, 2,6-dichloro-N-methoxy-N-methylisonicotinamide serves as a valuable precursor in the synthesis of various organic compounds, further expanding its applications in the field of chemistry and related industries.

Upstream product

• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 185319-20-4 1-(2,6-dichloropyridin-4-yl)ethan-1-one 
• 1239359-22-8 (S)-N₂-[1-(4-fluorophenyl)ethyl]-N₆-(pyrazin-2-yl)-4-(1H-pyrazol-3-yl)pyridine-2,6-diamine 
• 1239361-93-3 (S)-1-{2-[1-(4-fluorophenyl)ethylamino]-6-(pyrazin-2-ylamino)pyridin-4-yl}ethanone 
• 1239363-05-3 (S)-N₂-[1-(4-fluorophenyl)ethyl]-N₆-(pyrazin-2-yl)-4-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)pyridine-2,6-diamine 
• 1239363-30-4 (S)-1-{2-chloro-6-[1-(4-fluorophenyl)ethylamino]pyridin-4-yl}ethanone 
• 1353056-47-9 (2,6-dichloropyridin-4-yl)(phenyl)methanone 
• 1187669-40-4 4-(2,6-dichloro-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 881402-42-2 C₁₂H₇ClFNO 

Relevant articles and documents

Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors

A series of novel isocombretapyridines were designed and synthesized based on a lead compound isocombretastatin A-4 (isoCA-4) by replacing 3,4,5-trimethoxylphenyl with substituent pyridine nucleus. The MTT assay results showed that compound 20a possessed the most potent activities against all tested cell lines with IC50 values at nanomolar concentration ranges. Moreover, 20a inhibited tubulin polymerization at a micromolar level and also displayed potent anti-vascular activity in vitro. Further mechanistic studies were conducted to demonstrate that compound 20a could bind to the colchicine site of tubulin,and disrupte the cell microtubule networks, induce G2/M phase arrest, promote apoptosis and depolarize mitochondria of K562 cells in a dose-dependent manner. Notably, 20a exhibited more potent tumor growth inhibition activity with 68.7% tumor growth inhibition than that of isoCA-4 in H22 allograft mouse model without apparent toxicity. The present results suggested that compound 20a may serve as a promising potent microtubule-destabilizing agent candidate for the development of therapeutics to treat cancer.

Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents

Further optimization of the trimethoxyphenyl scaffold of parent chalcone compound (2a) by introducing a pyridine ring afforded a series of novel pyridine-chalcone derivatives as potential anti-tubulin agents. All the target compounds were evaluated for their antiproliferative activities. Among them, representative compound 16f exhibited the most potent activity with the IC50 values ranging from 0.023 to 0.045 μM against a panel of cancer cell lines. Further mechanism study results demonstrated that compound 16f effectively inhibited the microtubule polymerization by binding to the colchicine site of tubulin. Moreover, cellular mechanism studies disclosed that 16f caused G2/M phase arrest, induced cell apoptosis and disrupted the intracellular microtubule network. Also, 16f reduced the cell migration and disrupted the capillary-like tube formation of human umbilical vein endothelial cells (HUVECs). Importantly, 16f significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, which was stronger than the reference compound CA-4, indicating that it is worthy to investigate 16f as a potent microtubule-destabilizing agent for cancer therapy.

TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS

The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or inhibiting the PI3K-AKT-MTOR pathway, and methods of treating diseases that are associated with autophagy or the PI3K-AKT-MTOR pathway.

POTASSIUM CHANNEL MODULATORS

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

Therapeutic agent pcnsl (by machine translation)

The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.

AMINOPYRAZINE DERIVATIVE AND MEDICINE

The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. (I) X is CH or N; R1 is a halogen atom,; and R2 is H, a halogen atom, CN, [2], [3], [8], [9], an —O-alkyl, an —O-(saturated ring), etc. [2]: —C(RC)(RD)(RE) (RC to RE each are H, an alkyl, etc.) [3]: —N(RF)(RG) (RF and RG each are H, OH, amino, a (hetero)aryl, etc.) [8]: —C(═O)RL (RL is an alkyl, OH, an alkoxy, amino, etc.) [9]: a (substituted)phenyl; (II) X is >C—C(—O)R3 (R3 is a (substituted)amino, an alkoxy, OH, etc.); R1 is a halogen atom; R2 is H; R3 is H or OH; and R3 and R4 each are H or an alkyl.

4-Pyridylanilinothiazoles that selectively target von Hippel - Lindau deficient renal cell carcinoma cells by inducing autophagic cell death

Renal cell carcinomas (RCC) are refractory to standard therapy with advanced RCC having a poor prognosis; consequently treatment of advanced RCC represents an unmet clinical need. The von Hippel-Lindau (VHL) tumor suppressor gene is mutated or inactivated in a majority of RCCs. We recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure-activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in vitro using paired RCC4 cell lines. A contour map describing the relative spatial contributions of different chemical features to potency illustrates a region, adjacent to the pyridyl ring, with potential for further development. Examples probing this domain validated this approach and may provide the opportunity to develop this novel chemotype as a targeted approach to the treatment of RCC. 2009 American Chemical Society.

HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT

Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives

The present invention relates to a method of protecting plants against attack or infestation by phytopathogenic organisms, such as nematodes or especially microorganisms, preferably fungi, bacteria and viruses, or combinations of two or more of these organisms, by applying at least one compound of the formula (I): wherein n is 0 or 1, R1 is halogen, alkoxy, haloalkyl, haloalkoxy or alkyl, R2 is hydrogen, halogen, alkyl, haloalkyl, alkoxy or haloalkoxy, each of R3, R4 and R5 is, independently of the others, hydrogen, lower alkyl or halogen, and R6 is as defined in claim 1. The invention also relates to new compounds of formula (I), their preparation, use and compositions comprising said compound.